Document is current

Article History

Received: 25 August 2021

Revised: 15 February 2022

Accepted: 21 February 2022

First Online: 23 March 2022

Declarations

:

: The scientific guarantor of this publication is Dr. Zhaoxiang Ye.

: The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

: One of the authors (Yue Ma) has significant statistical expertise.

: Data of this study was collected from a prospective clinical trial, entitled “The Technical Operations and Standard Clinical Application Protocol of Cone Beam Breast Computed Tomography in Diagnosis and Treatment of Breast Cancer,” in which informed consent including an agreement of any further retrospective analysis was obtained from each patient at the time of the enrollment.

: Institutional Review Board approval was obtained (bc2016039).

: The study subjects were collected from a prospective clinical trial, aiming to explore the clinical application guide of CBBCT. There have been several publications which share the same cohort with the current study regarding the diagnosis and molecular subtyping of breast cancer as follows. However, we investigated the BPE level on CE-CBBCT images that had not been evaluated.1 Wang Y, Ma Y, Zhu Y et al (2021) Value of cone-beam breast CT in differentiating benign from malignant dense breast masses. Chin J Radiol 55:961-967 in Chinese2 Ma Y, Liu A, O'Connell AM et al (2021) Contrast-enhanced cone beam breast CT features of breast cancers: correlation with immunohistochemical receptors and molecular subtypes. Eur Radiol 31:2580-2589

: • retrospective• observational• performed at one institution